JP2023532080A5 - - Google Patents
Info
- Publication number
- JP2023532080A5 JP2023532080A5 JP2022580784A JP2022580784A JP2023532080A5 JP 2023532080 A5 JP2023532080 A5 JP 2023532080A5 JP 2022580784 A JP2022580784 A JP 2022580784A JP 2022580784 A JP2022580784 A JP 2022580784A JP 2023532080 A5 JP2023532080 A5 JP 2023532080A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- dota
- lys
- immune cells
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063045641P | 2020-06-29 | 2020-06-29 | |
| US63/045,641 | 2020-06-29 | ||
| PCT/US2021/039418 WO2022005994A1 (en) | 2020-06-29 | 2021-06-28 | C825 expressing immune cells and diagnostic uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023532080A JP2023532080A (ja) | 2023-07-26 |
| JP2023532080A5 true JP2023532080A5 (https=) | 2024-07-04 |
Family
ID=79315506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580784A Pending JP2023532080A (ja) | 2020-06-29 | 2021-06-28 | Ｃ８２５を発現する免疫細胞およびこれを使用する診断法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230348853A1 (https=) |
| EP (1) | EP4171621A4 (https=) |
| JP (1) | JP2023532080A (https=) |
| KR (1) | KR20230042698A (https=) |
| CN (1) | CN116096433A (https=) |
| CA (1) | CA3184225A1 (https=) |
| WO (1) | WO2022005994A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120187461A (zh) * | 2022-09-14 | 2025-06-20 | 生物权威(澳大利亚)有限责任公司 | 免疫细胞的体内检测 |
| WO2025176795A1 (en) * | 2024-02-20 | 2025-08-28 | Centre Hospitalier Universitaire Vaudois (Chuv) | T cell tracking |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107847584B (zh) * | 2015-02-09 | 2022-01-25 | 纪念斯隆凯特琳癌症中心 | 具有人a33抗原和dota金属复合物亲和力的多特异性抗体及其用途 |
| WO2017133175A1 (en) * | 2016-02-04 | 2017-08-10 | Nanjing Legend Biotech Co., Ltd. | Engineered mammalian cells for cancer therapy |
| EA201992546A1 (ru) * | 2017-04-24 | 2020-03-06 | Мемориал Слоан Кеттеринг Кэнсер Сентер | Средства на основе антител к cd33 |
| CN111212849A (zh) * | 2017-06-30 | 2020-05-29 | 纪念斯隆-凯特林癌症中心 | 用于癌症的过继性细胞疗法的组合物和方法 |
| CN112088169A (zh) * | 2018-03-12 | 2020-12-15 | 纪念斯隆凯特琳癌症中心 | 双特异性结合剂及其用途 |
| EP3561053A1 (en) * | 2018-04-26 | 2019-10-30 | Baylor College of Medicine | Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy |
| EP3958874A4 (en) * | 2019-04-23 | 2023-09-06 | The Trustees of The University of Pennsylvania | DOTA-BINDING CHIMERIC ANTIGEN RECEPTOR FOR CELLULAR THERAPY |
-
2021
- 2021-06-28 WO PCT/US2021/039418 patent/WO2022005994A1/en not_active Ceased
- 2021-06-28 EP EP21832450.7A patent/EP4171621A4/en active Pending
- 2021-06-28 CA CA3184225A patent/CA3184225A1/en active Pending
- 2021-06-28 US US18/003,646 patent/US20230348853A1/en active Pending
- 2021-06-28 JP JP2022580784A patent/JP2023532080A/ja active Pending
- 2021-06-28 CN CN202180052236.8A patent/CN116096433A/zh active Pending
- 2021-06-28 KR KR1020237002602A patent/KR20230042698A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240218075A1 (en) | Use of chimeric antigen receptor modified cells to treat cancer | |
| Menderes et al. | Immunotherapy and targeted therapy for cervical cancer: an update | |
| JP7127876B2 (ja) | 免疫療法のためのナノ粒子組成物及び方法 | |
| Zandberg et al. | A phase I dose escalation trial of MAGE-A3-and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) | |
| Klener et al. | Immunotherapy approaches in cancer treatment | |
| JP2020530989A5 (https=) | ||
| JP2023532080A5 (https=) | ||
| WO2018121605A1 (zh) | 一种多功能蛋白质 | |
| CN114729031A (zh) | 抗溶瘤病毒抗原抗体及其使用方法 | |
| US20200061167A1 (en) | Combination of listeria-based vaccine with anti-ctla-4 or anti-cd137 antibodies | |
| US20240148898A1 (en) | Protein fused with molecule capable of binding to immune checkpoint molecule and use of same | |
| Chen et al. | HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression | |
| Du et al. | From design to clinic: Engineered peptide nanomaterials for cancer immunotherapy | |
| CN104877028A (zh) | 抗dota嵌合抗原受体修饰的t细胞及其抗肿瘤的应用 | |
| Choi et al. | Engineering chimeric antigen receptor T cells to treat glioblastoma | |
| Salit et al. | Ins and outs of clinical trials with peptide-based vaccines | |
| Rumfiled et al. | Combination therapies for HPV-associated malignancies | |
| Kim et al. | Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110 | |
| WO2021139698A1 (zh) | 一种识别hpv抗原的t细胞受体及其编码序列 | |
| Mohit et al. | The contribution of NT‐gp96 as an adjuvant for increasing HPV16 E7‐specific immunity in C57BL/6 mouse model | |
| Zaloudik et al. | Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice | |
| Clifton et al. | Folate receptor α: a storied past and promising future in immunotherapy | |
| US20240269272A1 (en) | Vaccine composition comprising encoded adjuvant | |
| EP4053157A1 (en) | Disease antigen-fused protein, and use thereof | |
| Rennert et al. | 160 evaluation and development of dual and triple antigen targeting CAR-T engager proteins for Her2-positive CNS metastases and solid tumors |